HeartForce is pleased to announce its latest multi-center study, to occur at the end of March 2021, in Uzbekistan. The research study will take place in coordination with three renowned heart centres, located in Tashkent and Karshi. The study will involve 1500 enrolled patients and will be supervised by the Eurasian Heart Foundation (EAHF), headquartered in Zurich, Switzerland. Data obtained from this study will be used to consolidate the requirements necessary for FDA approval of HeartForce devices.
The EAHF is led by its founder and president, Prof.Dr.med.Dr.h.c.Paul R.Vogt, who also serves as the Director of Cardiovascular Surgery at University Hospital Zurich.